ZVRA — Zevra Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Zevra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-8.55	-41.5	-46	-106	83.2
Depreciation
Non-Cash Items	19.1	26.1	8.86	36.5	-56.3
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-0.357	-4.25	2.65	-7.07	-32.6
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	10.4	-18.7	-33.5	-69.7	-1.6
Capital Expenditures	-0.102	-0.093	-0.296	-6	-0.835
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-15.4	-36.6	-17.1	-16.2	19
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	-15.5	-36.7	-17.4	-22.2	18.1
Financing Cash Flow Items	73.9	-0.033	0.692	-1.44	-0.372
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	113	8.35	28.5	82.1	12.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	108	-46.9	-22.4	-9.26	28.6